These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 15634644)

  • 1. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY; Dai Y; Grant S
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
    Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells.
    Sinicrope FA; Penington RC; Tang XM
    Clin Cancer Res; 2004 Dec; 10(24):8284-92. PubMed ID: 15623604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
    Gao N; Dai Y; Rahmani M; Dent P; Grant S
    Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
    Pei XY; Dai Y; Grant S
    Leukemia; 2003 Oct; 17(10):2036-45. PubMed ID: 14513055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.
    Takada Y; Sethi G; Sung B; Aggarwal BB
    Mol Pharmacol; 2008 May; 73(5):1549-57. PubMed ID: 18287248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
    Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
    Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor.
    An J; Chervin AS; Nie A; Ducoff HS; Huang Z
    Oncogene; 2007 Feb; 26(5):652-61. PubMed ID: 16909121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
    Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
    Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
    Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
    Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
    Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C; Krystal G; Dent P; Grant S
    Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
    Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
    Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
    Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
    Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
    Dasmahapatra G; Lembersky D; Rahmani M; Kramer L; Friedberg J; Fisher RI; Dent P; Grant S
    Cancer Biol Ther; 2009 May; 8(9):808-19. PubMed ID: 19270531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.